SAN DIEGO, Dec. 30, 2024 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Takeda received regulatory approval…
SAN DIEGO, Dec. 30, 2024 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx’s VYVDURA (efgartigimod alfa…
Opdivo Qvantig represents the first and only subcutaneously administered PD-1 inhibitor Opdivo Qvantig demonstrated consistent efficacy and showed a comparable…
National homebuilder funds team members’ holiday inspired philanthropic initiatives SCOTTSDALE, Ariz., Dec. 30, 2024 /PRNewswire/ — For the eighth consecutive…